CN117356644A - 一种用于提高免疫力的咖啡保健品、制备方法及其应用 - Google Patents
一种用于提高免疫力的咖啡保健品、制备方法及其应用 Download PDFInfo
- Publication number
- CN117356644A CN117356644A CN202311036821.6A CN202311036821A CN117356644A CN 117356644 A CN117356644 A CN 117356644A CN 202311036821 A CN202311036821 A CN 202311036821A CN 117356644 A CN117356644 A CN 117356644A
- Authority
- CN
- China
- Prior art keywords
- parts
- coffee
- immunity
- extract
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013353 coffee beverage Nutrition 0.000 title claims abstract description 117
- 230000036039 immunity Effects 0.000 title claims abstract description 63
- 230000036541 health Effects 0.000 title claims abstract description 49
- 238000002360 preparation method Methods 0.000 title abstract description 21
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 68
- 239000005017 polysaccharide Substances 0.000 claims abstract description 68
- 150000004676 glycans Chemical class 0.000 claims abstract description 67
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract description 62
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims abstract description 62
- 239000000843 powder Substances 0.000 claims abstract description 60
- 239000000284 extract Substances 0.000 claims abstract description 53
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 48
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 48
- 235000008434 ginseng Nutrition 0.000 claims abstract description 48
- 150000003648 triterpenes Chemical class 0.000 claims abstract description 27
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims abstract description 26
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 claims abstract description 26
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 claims abstract description 26
- 235000009498 luteolin Nutrition 0.000 claims abstract description 26
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 23
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 23
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 22
- 240000000249 Morus alba Species 0.000 claims abstract description 22
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 22
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 21
- 235000017443 Hedysarum boreale Nutrition 0.000 claims abstract description 21
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims abstract description 21
- 235000014676 Phragmites communis Nutrition 0.000 claims abstract description 21
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims abstract description 21
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 20
- 241000234435 Lilium Species 0.000 claims abstract description 20
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 20
- 235000006533 astragalus Nutrition 0.000 claims abstract description 20
- 229930182490 saponin Natural products 0.000 claims abstract description 20
- 150000007949 saponins Chemical class 0.000 claims abstract description 20
- 235000007516 Chrysanthemum Nutrition 0.000 claims abstract description 19
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims abstract description 19
- 240000002505 Pogostemon cablin Species 0.000 claims abstract description 19
- 235000011751 Pogostemon cablin Nutrition 0.000 claims abstract description 19
- 208000007514 Herpes zoster Diseases 0.000 claims abstract description 15
- 241000213006 Angelica dahurica Species 0.000 claims abstract description 13
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims abstract description 12
- 240000001949 Taraxacum officinale Species 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 82
- 239000011858 nanopowder Substances 0.000 claims description 72
- 239000000725 suspension Substances 0.000 claims description 65
- 238000000855 fermentation Methods 0.000 claims description 56
- 230000004151 fermentation Effects 0.000 claims description 56
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 42
- 230000001804 emulsifying effect Effects 0.000 claims description 40
- 241000222336 Ganoderma Species 0.000 claims description 27
- 239000011259 mixed solution Substances 0.000 claims description 26
- 230000003834 intracellular effect Effects 0.000 claims description 25
- 239000008367 deionised water Substances 0.000 claims description 24
- 229910021641 deionized water Inorganic materials 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 23
- 239000000243 solution Substances 0.000 claims description 23
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 19
- -1 octyl gluconate Chemical compound 0.000 claims description 19
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 16
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 claims description 16
- 239000011324 bead Substances 0.000 claims description 16
- MDXRFOWKIZPNTA-UHFFFAOYSA-L butanedioate;iron(2+) Chemical compound [Fe+2].[O-]C(=O)CCC([O-])=O MDXRFOWKIZPNTA-UHFFFAOYSA-L 0.000 claims description 16
- 229960001604 ferrous succinate Drugs 0.000 claims description 16
- 238000004108 freeze drying Methods 0.000 claims description 16
- 229940050410 gluconate Drugs 0.000 claims description 16
- 229910052726 zirconium Inorganic materials 0.000 claims description 16
- 230000002708 enhancing effect Effects 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 15
- 241000628997 Flos Species 0.000 claims description 10
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 10
- 229960001948 caffeine Drugs 0.000 claims description 10
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 10
- 238000004659 sterilization and disinfection Methods 0.000 claims description 10
- 238000012258 culturing Methods 0.000 claims description 9
- 238000010947 wet-dispersion method Methods 0.000 claims description 9
- 230000009471 action Effects 0.000 claims description 8
- 239000003513 alkali Substances 0.000 claims description 8
- 239000002131 composite material Substances 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 230000010355 oscillation Effects 0.000 claims description 8
- 239000012071 phase Substances 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 238000003760 magnetic stirring Methods 0.000 claims description 7
- 239000007790 solid phase Substances 0.000 claims description 6
- 241000208340 Araliaceae Species 0.000 claims 4
- 238000009098 adjuvant therapy Methods 0.000 claims 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 2
- 240000004371 Panax ginseng Species 0.000 description 42
- 239000000047 product Substances 0.000 description 38
- 230000000694 effects Effects 0.000 description 31
- 210000004072 lung Anatomy 0.000 description 22
- 235000017709 saponins Nutrition 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 17
- 210000000952 spleen Anatomy 0.000 description 17
- 241000245665 Taraxacum Species 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 201000010099 disease Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 239000000796 flavoring agent Substances 0.000 description 14
- 235000019634 flavors Nutrition 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 206010011224 Cough Diseases 0.000 description 13
- 210000002784 stomach Anatomy 0.000 description 13
- 230000007812 deficiency Effects 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 238000011282 treatment Methods 0.000 description 11
- 235000009508 confectionery Nutrition 0.000 description 10
- 235000019640 taste Nutrition 0.000 description 10
- 230000010415 tropism Effects 0.000 description 9
- 238000003860 storage Methods 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 7
- 206010012735 Diarrhoea Diseases 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 206010019233 Headaches Diseases 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 231100000869 headache Toxicity 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 201000009240 nasopharyngitis Diseases 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 208000006820 Arthralgia Diseases 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 4
- 208000033809 Suppuration Diseases 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000000859 sublimation Methods 0.000 description 4
- 230000008022 sublimation Effects 0.000 description 4
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 206010039424 Salivary hypersecretion Diseases 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 201000003453 lung abscess Diseases 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 208000026451 salivation Diseases 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 229940126680 traditional chinese medicines Drugs 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010003011 Appendicitis Diseases 0.000 description 2
- 206010013954 Dysphoria Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 208000000616 Hemoptysis Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 206010024642 Listless Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 229940124584 antitussives Drugs 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 229940107666 astragalus root Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229930182494 ginsenoside Natural products 0.000 description 2
- 229940089161 ginsenoside Drugs 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 235000011477 liquorice Nutrition 0.000 description 2
- 208000017971 listlessness Diseases 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 230000024121 nodulation Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- JAWSHISYWRRQQQ-HFAKWTLXSA-N patchoulenone Chemical compound C[C@@H]1CC[C@@H]2C(=O)C3=C(C)CC[C@]13C2(C)C JAWSHISYWRRQQQ-HFAKWTLXSA-N 0.000 description 2
- GGHMUJBZYLPWFD-UHFFFAOYSA-N patchoulialcohol Chemical compound C1CC2(C)C3(O)CCC(C)C2CC1C3(C)C GGHMUJBZYLPWFD-UHFFFAOYSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FBFMBWCLBGQEBU-GYMUUCMZSA-N 20-gluco-ginsenoside-Rf Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FBFMBWCLBGQEBU-GYMUUCMZSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 241001529821 Agastache Species 0.000 description 1
- 240000004510 Agastache rugosa Species 0.000 description 1
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 1
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- HYPFYJBWSTXDAS-UHFFFAOYSA-N Ginsenoside Rd Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C4CCC5C(C)(C)C(CCC5(C)C4CC(O)C23C)OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C HYPFYJBWSTXDAS-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010069767 H1N1 influenza Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- GGHMUJBZYLPWFD-MYYUVRNCSA-N Patchouli alcohol Natural products O[C@@]12C(C)(C)[C@H]3C[C@H]([C@H](C)CC1)[C@]2(C)CC3 GGHMUJBZYLPWFD-MYYUVRNCSA-N 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000711902 Pneumovirus Species 0.000 description 1
- 241000756042 Polygonatum Species 0.000 description 1
- 241000037831 Polygonatum sibiricum Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038084 Rectocele Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- ZIHHMGTYZOSFRC-UWWAPWIJSA-M cobamamide Chemical compound C1(/[C@](C)(CCC(=O)NC[C@H](C)OP(O)(=O)OC2[C@H]([C@H](O[C@@H]2CO)N2C3=CC(C)=C(C)C=C3N=C2)O)[C@@H](CC(N)=O)[C@]2(N1[Co+]C[C@@H]1[C@H]([C@@H](O)[C@@H](O1)N1C3=NC=NC(N)=C3N=C1)O)[H])=C(C)\C([C@H](C/1(C)C)CCC(N)=O)=N\C\1=C/C([C@H]([C@@]\1(CC(N)=O)C)CCC(N)=O)=N/C/1=C(C)\C1=N[C@]2(C)[C@@](C)(CC(N)=O)[C@@H]1CCC(N)=O ZIHHMGTYZOSFRC-UWWAPWIJSA-M 0.000 description 1
- 235000006279 cobamamide Nutrition 0.000 description 1
- 239000011789 cobamamide Substances 0.000 description 1
- 239000008373 coffee flavor Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 description 1
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000007709 nanocrystallization Methods 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000015339 staphylococcus aureus infection Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- UOJAEODBOCLNBU-UHFFFAOYSA-N vinaginsenoside R4 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O UOJAEODBOCLNBU-UHFFFAOYSA-N 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F5/00—Coffee; Coffee substitutes; Preparations thereof
- A23F5/24—Extraction of coffee; Coffee extracts; Making instant coffee
- A23F5/36—Further treatment of dried coffee extract; Preparations produced thereby, e.g. instant coffee
- A23F5/40—Further treatment of dried coffee extract; Preparations produced thereby, e.g. instant coffee using organic additives, e.g. milk, sugar
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F5/00—Coffee; Coffee substitutes; Preparations thereof
- A23F5/24—Extraction of coffee; Coffee extracts; Making instant coffee
- A23F5/246—Addition of, or treatment with, enzymes or microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/532—Agastache, e.g. giant hyssop
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8967—Lilium, e.g. tiger lily or Easter lily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8998—Hordeum (barley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Immunology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种用于提高免疫力的咖啡保健品、制备方法及其应用,灵芝多糖和灵芝总三萜(灵芝提取液)0.8‑3份,人参茎叶总皂苷(人参茎叶提取液)0.6‑3.2份,黄芪2‑8份,黄精2‑8份,炙甘草2‑8份,百合2‑6份,广藿香2‑6份,薏苡仁2‑6份,白芷2‑6份,桑叶2‑6份,木犀草苷(菊花提取液)2‑5.8份,金银花2‑6份,蒲公英2‑6份,芦根2‑6份,冻干咖啡粉0.8‑3份、麦芽提取物1.6‑6份,麦芽提取物中活性多糖含量为80%‑92%;本发明提供一种用于提高免疫力的咖啡保健品,利用该保健品提高人体免疫力,辅助治疗新冠感冒,并可用于辅助治疗带状疱疹,满足咖啡消费者的同时,具有增强身体免疫力的效果;并提供了咖啡保健品的制备方法。
Description
技术领域
本发明属于医药制剂领域,特别是一种用于提高免疫力的咖啡保健品、制备方法及其应用。
背景技术
上海充分发挥中医药的“治未病”优势,在疫情初期就下发了《2022年春季易感人群外感疫病中药内服预防方案》上海市中医药管理局抽样调查了显示中药防疫代茶饮进行预防干预是有明显保护效用,但中药代茶饮因口感不佳,适用范围窄,冲泡便捷性差等问题在使用方面问题颇多。中药提取物颗粒在咖啡中配伍使用不仅会引入诸多诸如糊精之类的添加剂,而且提取物大多经过高温煎煮及喷雾干燥,其中风味成分挥发较多,苦味突出,影响咖啡风味;此外,人体免疫力低下即会成为肺炎病毒的易感人群,免疫力低下的人群即使康复也会出现带状疱疹后遗症,给患者带来痛苦,同时精神低迷,为患者康复孤傲成中的工作生活带来困扰;为了解决以上问题,本发明选取了多种药食同源中药,采用了纳米化加工方法,制备了一种增强免疫力的中药组合物咖啡饮品。
发明内容
本发明的目的是提供一种用于提高免疫力的咖啡保健品、制备方法及其应用,要解决的技术问题是如何提供一种用于提高免疫力的咖啡保健品,利用该保健品提高人体免疫力,辅助治疗感冒,并可用于治疗带状疱疹,满足咖啡消费者的同时,具有增强身体免疫力的效果;并提供了咖啡保健品的制备方法。
为实现上述目的,本发明采用如下技术方案;
本发明提供一种用于提高免疫力的咖啡保健品,包括以下重量份数计的组分:芝多糖和灵芝总三萜(灵芝提取液)0.8-3份,人参茎叶总皂苷(人参茎叶提取液)0.6-3.2份,黄芪2-8份,黄精2-8份,炙甘草2-8份,百合2-6份,广藿香2-6份,薏苡仁2-6份,白芷2-6份,桑叶2-6份,木犀草苷(菊花提取液)2-5.8份,金银花2-6份,蒲公英2-6份,芦根2-6份,冻干咖啡粉0.8-3份、麦芽提取物1.6-6份,麦芽提取物中活性多糖含量为80%-92%。
灵芝:【性味与归经】甘,平。归心、肺、肝、肾经。【功能与主治】补气安神,止咳平喘。用于心神不宁,失眠心悸,肺虚咳喘,虚劳短气,不思饮食。灵芝多糖和灵芝总三萜从灵芝中提取;灵芝多糖和灵芝总三萜可提高机体免疫力,在癌症病人经放疗、化疗机体免疫力受损的情况下,与放疗、化疗配合可达到治愈疾病的目的;灵芝多糖和灵芝总三萜还可抑制过敏反应介质的释放,从而阻断非特异性反应的发生,可抑制手术后癌细胞复发和转移。人参叶:【性味与归经】苦、甘,寒。归肺、胃经。【功能与主治】补气,益肺,祛暑,生津。用于气虚咳嗽,暑热烦躁,津伤口渴,头目不清,四肢倦乏。本申请中使用的人参茎叶总皂苷从人参叶中提取,人参叶中人参皂苷、人参皂苷Re和人参皂苷Rd的含量高于人参。
黄芪:【性味与归经】甘,微温。归肺、脾经。【功能与主治】补气升阳,固表止汗,利水消肿,生津养血,行滞通痹,托毒排脓,敛疮生肌。用于气虚乏力,食少便溏,中气下陷,久泻脱肛,便血崩漏,表虚自汗,气虚水肿,内热消渴,血虚萎黄,半身不遂,痹痛麻木,痈疽难溃,久溃不敛。
黄精:【性味与归经】甘,平。归脾、肺、肾经。【功能与主治】补气养阴,健脾,润肺,益肾。用于脾胃气虚,体倦乏力,胃阴不足,口干食少,肺虚燥咳,劳嗽咳血,精血不足,腰膝酸软,须发早白,内热消渴。
甘草:【性味与归经】甘,平。归心、肺、脾、胃经。【功能与主治】补脾益气,清热解毒,祛痰止咳,缓急止痛,调和诸药。用于脾胃虚弱,倦怠乏力,心悸气短,咳嗽痰多,脘腹、四肢挛急疼痛,痈肿疮毒,缓解药物毒性、烈性。炙甘草是用蜜炮制的甘草。
百合:【性味与归经】甘,寒。归心、肺经。【功能与主治】养阴润肺,清心安神。用于阴虚燥咳,劳嗽咳血,虚烦惊悸,失眠多梦,精神恍惚。
广藿香:【性味与归经】辛,微温。归脾、胃、肺经。【功能与主治】芳香化浊,和中止呕,发表解暑。用于湿浊中阻,脘痞呕吐,暑湿表证,湿温初起,发热倦怠,胸闷不舒,寒湿闭暑,腹痛吐泻,鼻渊头痛。
薏苡仁:【性味与归经】甘、淡,凉。归脾、胃、肺经。【功能与主治】利水渗湿,健脾止泻,除痹,排脓,解毒散结。用于水肿,脚气,小便不利,脾虚泄泻,湿痹拘挛,肺痈,肠痈,赘疣,癌肿。
白芷:【性味与归经】辛,温。归胃、大肠、肺经。【功能与主治】解表散寒,祛风止痛,宣通鼻窍,燥湿止带,消肿排脓。用于感冒头痛,眉棱骨痛,鼻塞流涕,鼻鼽,鼻渊,牙痛,带下,疮疡肿痛。
桑叶:【性味与归经】甘、苦,寒。归肺、肝经。【功能与主治】疏散风热,清肺润燥,清肝明目。用于风热感冒,肺热燥咳,头晕头痛,目赤昏花。
菊花:【性味与归经】甘、苦,微寒。归肺、肝经。【功能与主治】散风清热,平肝明目,清热解毒。用于风热感冒,头痛眩晕,目赤肿痛,眼目昏花,疮痈肿毒。木犀草苷由菊花提取,是一种天然黄酮类化合物,存在于多种植物中。具有多种药理活性,如消炎、抗过敏、抗肿瘤等。具有治疗止咳、祛痰、消炎的功效。木犀草苷有较强的呼吸道杀菌作用。
金银花:【性味与归经】甘,寒。归肺、心、胃经。【功能与主治】清热解毒,疏散风热。用于痈肿疔疮,喉痹,丹毒,热毒血痢,风热感冒,温病发热。
蒲公英:【性味与归经】苦、甘,寒。归肝、胃经。【功能与主治】清热解毒,消肿散结,利尿通淋。用于疔疮肿毒,乳痈,瘰疬,目赤,咽痛,肺痈,肠痈,湿热黄疸,热淋涩痛。
芦根:【性味与归经】甘,寒。归肺、胃经。【功能与主治】清热泻火,生津止渴,除烦,止呕,利尿。用于热病烦渴,肺热咳嗽,肺痈吐脓,胃热呕哕,热淋涩痛。
麦芽提取物:含有多种人体必需氨基酸和非必需氨基酸、活性多糖,是一种纯天然的营养风味增强物质,活性多糖可促进免疫功能,包括但不限于以下几项:
(1)提高巨噬细胞的吞噬能力,诱导白细胞介素1(IL-1)和肿瘤坏死因子(TNF)的生成等;
(2)促进T细胞增殖,诱导其分泌白细胞介素2(IL-2)等;
(3)促进淋巴因子激活的杀伤细胞(LAK)活性;
(4)提高B细胞活性,增加多种抗体的分泌,加强机体的体液免疫功能等;
(5)通过不同途径激活补体系统,通过替代通路激活补体等。
作为优选方案,冻干咖啡粉的咖啡因含量为0.8%;灵芝提取液为灵芝多糖和灵芝总三萜;人参茎叶提取液为人参茎叶总皂苷;菊花提取液为木犀草苷。
另外,本发明还提供了一种用于提高免疫力的咖啡保健品的制备方法,具体步骤如下。
a、制备初级混悬液:将黄芪,黄精,炙甘草,百合,广藿香,薏苡仁,白芷,桑叶,金银花,蒲公英和芦根2-6份制备成中药纳米粉A,过200-625目筛,称取一定量的前述中药纳米粉A加入到去离子水中,利用800rpm磁力搅拌10min混合均匀,制得中药粉混悬液,混悬液浓度比例为0.1-30%;混悬液首先转移至初级乳化分散机中进行初步粉碎一段时间,获得初级混悬液;中药粉混悬液在初级乳化分散机中的作用时间为5-30min,循环次数1-3次;
b、制备灵芝多糖和灵芝总三萜(灵芝提取液):
b1:将麦芽提取物分为两份:即B1和B2,其中B1是B2的0.5倍;
b2:将灵芝菌丝体溶解在去离子水中发酵24h-36h后,在灵芝菌丝体发酵液中加入鼠李糖乳杆菌LGG发酵液和麦芽提取物B1,并加入琥珀酸亚铁和葡萄糖酸辛,前述混合液发酵培养,发酵培养0.5-3天后,得到发酵液;
b3:将b2步骤中取得的发酵液中加入稀碱,在680w的超声功率下超声震荡15-25min,其中水相与固相比为28:1的条件下,得到细胞内多糖和细胞外多糖混合液;
c、将人参茎叶提取液(人参茎叶总皂苷)和菊花提取液(木犀草苷)加入到b3中得到的细胞内多糖和细胞外多糖混合液,搅拌均匀,再加入麦芽提取物B2,得到混合液C:其中,人参茎叶提取液和菊花提取液的制备方法为现有技术,不再赘述。
d:制备中药纳米粉复合咖啡饮品:将混合液C转移至低温连续乳化机中,连续循环乳化粉碎,收集混悬液,在冷冻干燥程序下固化干燥,获得中药纳米粉D,加入冻干咖啡粉,并与中药纳米粉D混合均匀,得到提高免疫力的咖啡保健品。
作为优选方案,步骤a中的中药纳米粉与去离子水的比例为(1-1.5):(2-3)。
作为优选方案,步骤b2中灵芝菌丝体发酵液与鼠李糖乳杆菌LGG发酵液和麦芽提取物A1的比例为1:1。
作为优选方案,步骤b2中琥珀酸亚铁和葡萄糖酸辛与灵芝菌丝体发酵液的比例为0.5:1。
作为优选方案,步骤b3中细胞内多糖和细胞外多糖得率为20-30mg/g。
作为优选方案,步骤d中低温连续湿法分散乳化机采用0.03-0.8mm锆珠,锆珠添加量为腔体体积的65%-75%,转速为500rpm-2000rpm,时间为0.5h-6h;
纳米粉悬浮液在-50℃的温度下预冻时间为1h-2h;
纳米粉悬浮液冷冻干燥升华时间为12-48h,真空度为10-30Pa;
干燥粉末含水量小于5%,采用紫外线照射6-12h消毒。
此外,本发明还提供了一种用于提高免疫力的咖啡保健品的应用方法,咖啡保健品中咖啡的浓度为2%-18%。
作为优选方案,提高免疫力的咖啡保健品可用于辅助治疗带状疱疹。
作为优选方案,本品不含防腐剂。
与现有技术相比,本发明具有如下的有益效果。
1,灵芝多糖和灵芝总三萜(灵芝提取液)可以增强抵抗力、抑制病毒复制、控制异常发炎、平衡ACE/ACE2,减轻慢性病对身体的负担,对预防及调节肺炎具有良好功效。研究发现人参中的人参皂苷,黄芪中的黄芪甲甘等候选成分,黄精中的黄精多糖,甘草中的甘草多糖等成分被证实能提高人体免疫力并与机体神经活体配体-受体相互作用、钙信号、T细胞受体、cAMP以及趋化因子等相关信号通路有着密切关联性。此外藿香中的广藿香醇、广藿香酮可以抗H1N1流感病毒、柯萨奇病毒,抗金黄色葡萄球菌感染,改善胃肠道功能,缓解恶心、大便溏薄等胃肠道症状;薏苡仁中的多糖可以调节免疫情况,提升免疫力;桑叶中的生物碱可以抑制病毒繁殖,金银花具有光谱的抗菌作用,其中的绿原酸和咖啡酸,可以有效抑制甲型流感病毒、单纯疱疹病毒等;芦根中的多糖均有调节免疫,抑制病毒繁殖等作用。上述均为药食同源类中药,安全性高,味道较易接受,非常适合用于制备增强免疫力保健功效的灵芝咖啡。
2,人体感染病毒主要是由病毒趁机入侵人体而发病;而内在因素则是由于人体正气不足,也就是中医所说的“邪之所凑,其气必虚”。新型冠状病毒所致的主要病理因素有“湿、寒、热、浊、虚”等,有医家将之纳入“湿温病”、“寒湿疫”、“湿毒疫”、“春温”等范畴。中医专家通过对百余例患者的诊治后,认为其病位在肺脾,湿邪困脾闭肺,气机升降失司,总结肺炎的基本病机为“湿、毒、瘀、闭”。据此形成的扶正益气,驱邪除湿配方,方中灵芝补气,止咳,提高免疫力,正所谓“正气存内,邪不可干”,提升正气增强人体自身抗病能力是防治疫病的先决条件。配合扶正益气的人参、黄芪、黄精、甘草,以及驱邪除湿,解表清热的藿香、薏苡仁、白芷、桑叶、菊花、金银花、芦根等中药。注重“防重于治、防治结合”,借以咖啡醇厚的味道调和掩盖中药风味,提供了一种口感香醇浓郁的辅助防疫灵芝咖啡,方法简便、易操作且行之有效,适合推广于大众用以防治疫病,提升正气所用。
3,麦芽提取物是一种来源于谷物的天然食品,含有丰富的麦芽糖、果糖、葡萄糖、蛋白质、小分子肽、人体必须的氨基酸和多种维生素、矿物质,麦芽提取物的添加不仅能够提升产品的颜色、香气、风味等感官特征,也能提高灵芝多糖和灵芝总三萜(灵芝提取液)的产量。
4,木樨草苷由菊花提取,是一种天然黄酮类化合物,存在于多种植物中。具有多种药理活性,如消炎、抗过敏、抗肿瘤等。具有治疗止咳、祛痰、消炎的功效。木犀草苷有较强的呼吸道杀菌作用。木犀草苷的加入可以有效提高咖啡液的稳定性,同时起到止咳祛痰和抗炎的作用,从而与其他中药成份共同起到提高人体免疫力,辅助治疗感冒的作用。
5,低温连续湿法分散乳化研磨制备工艺简单,安全高效,产品稳定性高,将低温湿法研磨技术应用于中药粉末制备,不仅能够保证活性成分快速溶出,又能有效保护活性物质避免因高温研磨产生热化学反应导致损失,更好的保留了中药中挥发性风味物质,提高产品产量的同时,增加了饮品的口感。
本发明的其它特征和优点将在随后的说明书中阐述,并且部分地从说明书中变得显而易见,或者通过实施本发明而了解。本发明的主要目的和其它优点可通过在说明书中所特别指出的方案来实现和获得。
具体实施方式
下面结合具体实施例对本发明进行详细说明。以下实施例将有助于本领域的技术人员进一步理解本发明,但不以任何形式限制本发明。应当指出的是,对本领域的普通技术人员来说,在不脱离本发明构思的前提下,还可以做出若干变形和改进。这些都属于本发明的保护范围。
第一部分:药物制剂部分
实施例1
本实施例涉及一种用于提高免疫力的咖啡保健品,包括以下重量份数计的组分:
灵芝多糖和灵芝总三萜(灵芝提取液)0.9份,人参茎叶总皂苷(人参茎叶提取液)1.5份,黄芪3份,黄精3份,炙甘草3份,百合2份,广藿香2份,薏苡仁2份,白芷2份,桑叶2份,木犀草苷(菊花提取液)2份,金银花2份,蒲公英2份,芦根2份,冻干咖啡粉0.9份、冻干咖啡粉的咖啡因含量为0.8%,麦芽提取物2份,麦芽提取物中活性多糖含量为83%。
一种用于提高免疫力的咖啡保健品的制备方法,具体步骤如下。
a、制备初级混悬液:将黄芪,黄精,炙甘草,百合,广藿香,薏苡仁,白芷,桑叶,金银花,蒲公英和芦根2-6份制备成中药纳米粉A,过200目和625目筛,称取一定量的前述中药纳米粉A加入到去离子水中,利用800rpm磁力搅拌10min混合均匀,制得中药粉混悬液,混悬液浓度比例为3-30%;混悬液首先转移至初级乳化分散机中进行初步粉碎一段时间,获得初级混悬液;中药粉混悬液在初级乳化分散机中的作用时间为10min,循环次数2次;中药纳米粉与去离子水的比例为1:2;
b、制备灵芝多糖和灵芝总三萜(灵芝提取液):
b1:将麦芽提取物分为两份:即B1和B2,其中B1是B2的0.5倍;
b2:将灵芝菌丝体溶解在去离子水中发酵24h-36h后,在灵芝菌丝体发酵液中加入鼠李糖乳杆菌LGG发酵液和麦芽提取物B1,并加入琥珀酸亚铁和葡萄糖酸辛,前述混合液发酵培养,发酵培养1天后,得到发酵液;灵芝菌丝体发酵液与鼠李糖乳杆菌LGG发酵液和麦芽提取物A1的比例为1:1;琥珀酸亚铁和葡萄糖酸辛与灵芝菌丝体发酵液的比例为0.5:1;b3:将b2步骤中取得的发酵液中加入稀碱,在680w的超声功率下超声震荡16min,其中水相与固相比为28:1的条件下,得到细胞内多糖和细胞外多糖混合液;细胞内多糖和细胞外多糖得率为20mg/g;
c、将人参茎叶总皂苷(人参茎叶提取液)和木犀草苷(菊花提取液)加入到b3中得到的细胞内多糖和细胞外多糖混合液,搅拌均匀,再加入麦芽提取物B2,得到混合液C:d:制备中药纳米粉复合咖啡饮品:将混合液C转移至低温连续乳化机中,连续循环乳化粉碎,收集混悬液,在冷冻干燥程序下固化干燥,获得中药纳米粉D,加入冻干咖啡粉,并与中药纳米粉D混合均匀,得到提高免疫力的咖啡保健品;其中低温连续湿法分散乳化机采用0.1mm锆珠,锆珠添加量为腔体体积的65%,转速为500rpm-1000rpm,时间为5.6h;
纳米粉悬浮液在-50℃的温度下预冻时间为1h;
纳米粉悬浮液冷冻干燥升华时间为12-48h,真空度为15Pa;
干燥粉末含水量小于5%,采用紫外线照射6h消毒。
实施例2
本实施例涉及一种用于提高免疫力的咖啡保健品,包括以下重量份数计的组分:
灵芝多糖和灵芝总三萜(灵芝提取液)1份,人参茎叶总皂苷(人参茎叶提取液)1.2份,黄芪3份,黄精3份,炙甘草3份,百合3份,广藿香3份,薏苡仁3份,白芷3份,桑叶3份,木犀草苷(菊花提取液)3份,金银花3份,蒲公英3份,芦根3份,冻干咖啡粉1.2份、冻干咖啡粉的咖啡因含量为0.8%,麦芽提取物1.6-6份,麦芽提取物中活性多糖含量为92%。
一种用于提高免疫力的咖啡保健品的制备方法,具体步骤如下。
a、制备初级混悬液:将黄芪,黄精,炙甘草,百合,广藿香,薏苡仁,白芷,桑叶,金银花,蒲公英和芦根2-6份制备成中药纳米粉A,过200-625目筛,称取一定量的前述中药纳米粉A加入到去离子水中,利用800rpm磁力搅拌10min混合均匀,制得中药粉混悬液,混悬液浓度比例为5-30%;混悬液首先转移至初级乳化分散机中进行初步粉碎一段时间,获得初级混悬液;中药粉混悬液在初级乳化分散机中的作用时间为15min,循环次数2次;中药纳米粉与去离子水的比例为1.2:2;
b、制备灵芝多糖和灵芝总三萜(灵芝提取液):
b1:将麦芽提取物分为两份:即B1和B2,其中B1是B2的0.5倍;
b2:将灵芝菌丝体溶解在去离子水中发酵24h-36h后,在灵芝菌丝体发酵液中加入鼠李糖乳杆菌LGG发酵液和麦芽提取物B1,并加入琥珀酸亚铁和葡萄糖酸辛,前述混合液发酵培养,发酵培养0.5-3天后,得到发酵液;灵芝菌丝体发酵液与鼠李糖乳杆菌LGG发酵液和麦芽提取物A1的比例为1:1;琥珀酸亚铁和葡萄糖酸辛与灵芝菌丝体发酵液的比例为0.5:1;
b3:将b2步骤中取得的发酵液中加入稀碱,在680w的超声功率下超声震荡15-25min,其中水相与固相比为28:1的条件下,得到细胞内多糖和细胞外多糖混合液;细胞内多糖和细胞外多糖得率为20-30mg/g;
c、将人参茎叶总皂苷(人参茎叶提取液)和木犀草苷(菊花提取液)加入到b3中得到的细胞内多糖和细胞外多糖混合液,搅拌均匀,再加入麦芽提取物B2,得到混合液C:d:制备中药纳米粉复合咖啡饮品:将混合液C转移至低温连续乳化机中,连续循环乳化粉碎,收集混悬液,在冷冻干燥程序下固化干燥,获得中药纳米粉D,加入冻干咖啡粉,并与中药纳米粉D混合均匀,得到提高免疫力的咖啡保健品;其中低温连续湿法分散乳化机采用0.03-0.8mm锆珠,锆珠添加量为腔体体积的65%,转速为500rpm-900rpm,时间为1.5h;
纳米粉悬浮液在-50℃的温度下预冻时间为1h;
纳米粉悬浮液冷冻干燥升华时间为12-48h,真空度为20Pa;
干燥粉末含水量小于5%,采用紫外线照射8h消毒。
实施例3
本实施例涉及一种用于提高免疫力的咖啡保健品,包括以下重量份数计的组分:
灵芝多糖和灵芝总三萜(灵芝提取液)2份,人参茎叶总皂苷(人参茎叶提取液)2份,黄芪3份,黄精3份,炙甘草3份,百合3份,广藿香3份,薏苡仁3份,白芷3份,桑叶3份,木犀草苷(菊花提取液)4份,金银花2.5份,蒲公英2.5份,芦根2份,冻干咖啡粉1.5份、冻干咖啡粉的咖啡因含量为0.8%,麦芽提取物4份,麦芽提取物中活性多糖含量为80%。。
一种用于提高免疫力的咖啡保健品的制备方法,具体步骤如下。
a、制备初级混悬液:将黄芪,黄精,炙甘草,百合,广藿香,薏苡仁,白芷,桑叶,金银花,蒲公英和芦根2-6份制备成中药纳米粉A,过200-625目筛,称取一定量的前述中药纳米粉A加入到去离子水中,利用800rpm磁力搅拌10min混合均匀,制得中药粉混悬液,混悬液浓度比例为0.1-30%;混悬液首先转移至初级乳化分散机中进行初步粉碎一段时间,获得初级混悬液;中药粉混悬液在初级乳化分散机中的作用时间为5-30min,循环次数1-3次;中药纳米粉与去离子水的比例为1:2;
b、制备灵芝多糖和灵芝总三萜(灵芝提取液):
b1:将麦芽提取物分为两份:即B1和B2,其中B1是B2的0.5倍;
b2:将灵芝菌丝体溶解在去离子水中发酵24h-36h后,在灵芝菌丝体发酵液中加入鼠李糖乳杆菌LGG发酵液和麦芽提取物B1,并加入琥珀酸亚铁和葡萄糖酸辛,前述混合液发酵培养,发酵培养2.5天后,得到发酵液;灵芝菌丝体发酵液与鼠李糖乳杆菌LGG发酵液和麦芽提取物A1的比例为1:1;琥珀酸亚铁和葡萄糖酸辛与灵芝菌丝体发酵液的比例为0.5:1;
b3:将b2步骤中取得的发酵液中加入稀碱,在680w的超声功率下超声震荡20min,其中水相与固相比为28:1的条件下,得到细胞内多糖和细胞外多糖混合液;细胞内多糖和细胞外多糖得率为25mg/g;
c、将人参茎叶总皂苷(人参茎叶提取液)和木犀草苷(菊花提取液)加入到b3中得到的细胞内多糖和细胞外多糖混合液,搅拌均匀,再加入麦芽提取物B2,得到混合液C:d:制备中药纳米粉复合咖啡饮品:将混合液C转移至低温连续乳化机中,连续循环乳化粉碎,收集混悬液,在冷冻干燥程序下固化干燥,获得中药纳米粉D,加入冻干咖啡粉,并与中药纳米粉D混合均匀,得到提高免疫力的咖啡保健品;其中低温连续湿法分散乳化机采用0.1mm锆珠,锆珠添加量为腔体体积的70%,转速为500rpm-1500rpm,时间为0.5h-6h;
纳米粉悬浮液在-50℃的温度下预冻时间为2h;
纳米粉悬浮液冷冻干燥升华时间为12-48h,真空度为25Pa;
干燥粉末含水量小于5%,采用紫外线照射9h消毒。
实施例4
本实施例涉及一种用于提高免疫力的咖啡保健品,包括以下重量份数计的组分:
灵芝多糖和灵芝总三萜(灵芝提取液)3份,人参茎叶总皂苷(人参茎叶提取液)3份,黄芪3份,黄精3份,炙甘草3份,百合3份,广藿香3份,薏苡仁3份,白芷3份,桑叶3份,木犀草苷(菊花提取液)5份,金银花3份,蒲公英3份,芦根3份,冻干咖啡粉3份、冻干咖啡粉的咖啡因含量为0.8%,麦芽提取物6份,麦芽提取物中活性多糖含量为92%。
一种用于提高免疫力的咖啡保健品的制备方法,具体步骤如下。
a、制备初级混悬液:将黄芪,黄精,炙甘草,百合,广藿香,薏苡仁,白芷,桑叶,金银花,蒲公英和芦根2-6份制备成中药纳米粉A,过200-625目筛,称取一定量的前述中药纳米粉A加入到去离子水中,利用800rpm磁力搅拌10min混合均匀,制得中药粉混悬液,混悬液浓度比例为0.1-30%;混悬液首先转移至初级乳化分散机中进行初步粉碎一段时间,获得初级混悬液;中药粉混悬液在初级乳化分散机中的作用时间为5-30min,循环次数1-3次;中药纳米粉与去离子水的比例为1.2:3
b、制备灵芝多糖和灵芝总三萜(灵芝提取液):
b1:将麦芽提取物分为两份:即B1和B2,其中B1是B2的0.5倍;
b2:将灵芝菌丝体溶解在去离子水中发酵24h-36h后,在灵芝菌丝体发酵液中加入鼠李糖乳杆菌LGG发酵液和麦芽提取物B1,并加入琥珀酸亚铁和葡萄糖酸辛,前述混合液发酵培养,发酵培养0.5-3天后,得到发酵液;灵芝菌丝体发酵液与鼠李糖乳杆菌LGG发酵液和麦芽提取物A1的比例为1:1;琥珀酸亚铁和葡萄糖酸辛与灵芝菌丝体发酵液的比例为0.5:1;
b3:将b2步骤中取得的发酵液中加入稀碱,在680w的超声功率下超声震荡15-25min,其中水相与固相比为28:1的条件下,得到细胞内多糖和细胞外多糖混合液;细胞内多糖和细胞外多糖得率为30mg/g;
c、将人参茎叶总皂苷(人参茎叶提取液)和木犀草苷(菊花提取液)加入到b3中得到的细胞内多糖和细胞外多糖混合液,搅拌均匀,再加入麦芽提取物B2,得到混合液C:d:制备中药纳米粉复合咖啡饮品:将混合液C转移至低温连续乳化机中,连续循环乳化粉碎,收集混悬液,在冷冻干燥程序下固化干燥,获得中药纳米粉D,加入冻干咖啡粉,并与中药纳米粉D混合均匀,得到提高免疫力的咖啡保健品;其中低温连续湿法分散乳化机采用0.03-0.8mm锆珠,锆珠添加量为腔体体积的65%-75%,转速为500rpm-2000rpm,时间为5.3h;
纳米粉悬浮液在-50℃的温度下预冻时间为1.5h;
纳米粉悬浮液冷冻干燥升华时间为42h,真空度为30Pa;
干燥粉末含水量小于5%,采用紫外线照射7h消毒。
实施例5
本实施例涉及一种用于提高免疫力的咖啡保健品,包括以下重量份数计的组分:
灵芝多糖和灵芝总三萜(灵芝提取液)3份,人参茎叶总皂苷(人参茎叶提取液)
3.2份,黄芪8份,黄精8份,炙甘草8份,百合6份,广藿香6份,薏苡仁6份,白芷6份,桑叶6份,木犀草苷(菊花提取液)5份,金银花6份,蒲公英6份,芦根6份,冻干咖啡粉3份、冻干咖啡粉的咖啡因含量为0.8%,麦芽提取物6份,麦芽提取物中活性多糖含量为92%。
实施例6
本实施例涉及一种用于提高免疫力的咖啡保健品,包括以下重量份数计的组分:
灵芝多糖和灵芝总三萜(灵芝提取液)3份,人参茎叶总皂苷(人参茎叶提取液)
3.2份,黄芪8份,黄精8份,炙甘草8份,百合2-6份,广藿香2-6份,薏苡仁2-6份,白芷2-6份,桑叶6份,木犀草苷(菊花提取液)5.8份,金银花6份,蒲公英6份,芦根6份,冻干咖啡粉2份、冻干咖啡粉的咖啡因含量为0.8%,麦芽提取物6份,麦芽提取物中活性多糖含量为80%。
实施例5和实施例6中一种用于提高免疫力的咖啡保健品的制备方法与实施例4相同。
第二部分:药效学部分
对照组1
本实施例涉及一种用于提高免疫力的咖啡保健品,由按重量份数计的如下组分组成:
灵芝多糖和灵芝总三萜(灵芝提取液)3份,人参茎叶总皂苷(人参茎叶提取液)3份,黄芪3份,黄精3份,炙甘草3份,百合3份,广藿香3份,薏苡仁3份,白芷3份,桑叶3份,木犀草苷(菊花提取液)3份,金银花3份,蒲公英3份,芦根3份,冻干咖啡粉3份、冻干咖啡粉的咖啡因含量为0.8%。
一种用于提高免疫力的咖啡保健品的制备方法,具体步骤如下。
a、制备初级混悬液:将黄芪,黄精,炙甘草,百合,广藿香,薏苡仁,白芷,桑叶,金银花,蒲公英和芦根2-6份制备成中药纳米粉A,过200-625目筛,称取一定量的前述中药纳米粉A加入到去离子水中,利用800rpm磁力搅拌10min混合均匀,制得中药粉混悬液,混悬液浓度比例为0.1-30%;混悬液首先转移至初级乳化分散机中进行初步粉碎一段时间,获得初级混悬液;中药粉混悬液在初级乳化分散机中的作用时间为5-30min,循环次数1-3次;中药纳米粉与去离子水的比例为(1-1.5):(2-3)
b、制备灵芝多糖和灵芝总三萜(灵芝提取液):
b1:将灵芝菌丝体溶解在去离子水中发酵24h-36h后,在灵芝菌丝体发酵液中加入鼠李糖乳杆菌LGG发酵液,并加入琥珀酸亚铁和葡萄糖酸辛,前述混合液发酵培养,发酵培养0.5-3天后,得到发酵液;灵芝菌丝体发酵液与鼠李糖乳杆菌LGG发酵液;琥珀酸亚铁和葡萄糖酸辛与灵芝菌丝体发酵液的比例为0.5:1;
b2:将b1步骤中取得的发酵液中加入稀碱,在680w的超声功率下超声震荡15-25min,其中水相与固相比为28:1的条件下,得到细胞内多糖和细胞外多糖混合液;细胞内多糖和细胞外多糖得率为12mg/g;
c、将人参茎叶总皂苷(人参茎叶提取液)和木犀草苷(菊花提取液)加入到b2中得到的细胞内多糖和细胞外多糖混合液,搅拌均匀,得到混合液C:
d:制备中药纳米粉复合咖啡饮品:将混合液C转移至低温连续乳化机中,连续循环乳化粉碎,收集混悬液,在冷冻干燥程序下固化干燥,获得中药纳米粉D,加入冻干咖啡粉,并与中药纳米粉D混合均匀,得到提高免疫力的咖啡保健品;其中低温连续湿法分散乳化机采用0.03-0.8mm锆珠,锆珠添加量为腔体体积的65%-75%,转速为500rpm-2000rpm,时间为0.5h-6h;
纳米粉悬浮液在-50℃的温度下预冻时间为1h-2h;
纳米粉悬浮液冷冻干燥升华时间为12-48h,真空度为10-30Pa;
干燥粉末含水量小于5%,采用紫外线照射6-12h消毒。
对照组2
本实施例涉及一种用于提高免疫力的咖啡保健品,包括以下重量份数计的组分:
人参茎叶总皂苷(人参茎叶提取液)3份,黄芪3份,黄精3份,炙甘草3份,百合3份,广藿香3份,薏苡仁3份,白芷3份,桑叶3份,木犀草苷(菊花提取液)5份,金银花3份,蒲公英3份,芦根3份,冻干咖啡粉3份、冻干咖啡粉的咖啡因含量为0.8%,麦芽提取物6份,麦芽提取物中活性多糖含量为92%。
一种用于提高免疫力的咖啡保健品的制备方法,具体步骤如下。
a、制备初级混悬液:将黄芪,黄精,炙甘草,百合,广藿香,薏苡仁,白芷,桑叶,金银花,蒲公英和芦根2-6份制备成中药纳米粉A,过200-625目筛,称取一定量的前述中药纳米粉A加入到去离子水中,利用800rpm磁力搅拌10min混合均匀,制得中药粉混悬液,混悬液浓度比例为0.1-30%;混悬液首先转移至初级乳化分散机中进行初步粉碎一段时间,获得初级混悬液;中药粉混悬液在初级乳化分散机中的作用时间为5-30min,循环次数1-3次;中药纳米粉与去离子水的比例为(1-1.5):(2-3)
b、将麦芽提取物分为两份:即B1和B2,其中B1是B2的0.5倍;
b2:将灵芝菌丝体溶解在去离子水中发酵24h-36h后,在灵芝菌丝体发酵液中加入鼠李糖乳杆菌LGG发酵液和麦芽提取物B1,并加入琥珀酸亚铁和葡萄糖酸辛,前述混合液发酵培养,发酵培养0.5-3天后,得到发酵液;灵芝菌丝体发酵液与鼠李糖乳杆菌LGG发酵液和麦芽提取物A1的比例为1:1;琥珀酸亚铁和葡萄糖酸辛与灵芝菌丝体发酵液的比例为0.5:1;
b3:将b2步骤中取得的发酵液中加入稀碱,在680w的超声功率下超声震荡15-25min,其中水相与固相比为28:1的条件下,得到细胞内多糖和细胞外多糖混合液;细胞内多糖和细胞外多糖得率为20-30mg/g;
c、将人参茎叶总皂苷(人参茎叶提取液)和木犀草苷(菊花提取液)加入到b3中得到的细胞内多糖和细胞外多糖混合液,搅拌均匀,再加入麦芽提取物B2,得到混合液C:d:制备中药纳米粉复合咖啡饮品:将混合液C转移至低温连续乳化机中,连续循环乳化粉碎,收集混悬液,在冷冻干燥程序下固化干燥,获得中药纳米粉D,加入冻干咖啡粉,并与中药纳米粉D混合均匀,得到提高免疫力的咖啡保健品;其中低温连续湿法分散乳化机采用0.03-0.8mm锆珠,锆珠添加量为腔体体积的65%-75%,转速为500rpm-2000rpm,时间为0.5h-6h;
纳米粉悬浮液在-50℃的温度下预冻时间为1h-2h;
纳米粉悬浮液冷冻干燥升华时间为12-48h,真空度为10-30Pa;
干燥粉末含水量小于5%,采用紫外线照射6-12h消毒。
2.1小鼠免疫力增强试验
2.1.1试验动物昆明种老龄小鼠(10月龄),体重18~22g,雄性,实验室温度(25±1)℃,相对湿度65%。
2.1.2受试样品:
受试样品1:为下述实施例1的咖啡粉。
受试样品2:为下述实施例2的咖啡粉。
受试样品3:为下述实施例3的咖啡粉。
受试样品4:为下述实施例4的咖啡粉。
受试样品5:为下述实施例5的咖啡粉。
受试样品6:为下述实施例6的咖啡粉。
2.1.3分组与给药
随机分为7组,每组50只,其分别为空白对照组(正常组)和受试样品1、2、3、4、5、6组。上述分别按人用剂量换算为小鼠用剂量加适量水溶解灌胃使用。各组动物在试验过程中自由饮用0.1%BSA酸化水,空白组每日灌服生理盐水,其它5组分别灌服受试样品,每日1次,连续30天。
2.1.4方法与结果
2.1.4.1脏器/体重比值测定:
试验终末,取10只小鼠,称重后处死小鼠,取出胸腺和脾脏,在电子分析天平上称重,计算脏/体比值。结果见下表1。
2.1.4.2小鼠迟发型变态反应(DTH):
试验结束前5d每组各取10只小鼠腹部皮肤脱毛,取50uL2,4-二硝基氟苯(以下简称DNFB)溶液涂抹小鼠腹部皮肤致敏,5d后取10uLDNFB溶液涂抹小鼠右耳两面,24h后处死小鼠,用打孔器取下左右耳壳8mm直径的耳片称重,以两耳片重量之差值表示DTH的程度。结果见下表1。
2.1.4.3NK细胞活性测定:
连续给药30d后,颈椎脱臼处死,取脾脏制成细胞悬液(效应细胞),取传代后24h的靶细胞(YAC-1细胞)加PRMI-1640完全培养液调整细胞浓度为4×105个/mL(靶细胞)。取靶细胞和效应细胞各100uL(效靶比50:1),加入U型96孔培养板,靶细胞自然释放孔加靶细胞和培养液各100uL,最大释放孔加靶细胞和NP40各100uL,上述各项均设三个复孔,于37℃、5%CO2培养箱中培养4h,然后将96孔培养板以1500rpm/min离心5min,每孔吸取上清液100uL置平底96孔培养板中,同时加入乳酸脱氢酶(LDH)基质液100uL,反应3min,每孔加入1mol/L的HCl30uL终止,用酶标仪在490nm处测定光密度值(OD)。结果见表1。
表1给药30天各组小鼠免疫参数变化
*P<0.05,空白对照组与受试样品比较样品对免疫器官脏器/体重比值的影响结果表明:试验中各组小鼠的生长状况良好,生理体征、外观、行为等均未见异常。试验不同样品组的胸腺/体重及脾脏/体重比值与对照组比较,差异不显著,表明各个样品组对胸腺指数和脾指数影响不大;样品组小鼠的迟发型变态反应(DTH)试验左右耳片重量差值均高于阴性对照组,与对照组(P>0.05)相比差异均有统计学意义,表明咖啡饮品对小鼠迟发型变态反应有一定的抑制作用。样品组小鼠的NK细胞活性明显高于阴性对照组,差异均有统计学意义(P>0.05),从数值看,各样品组高于阴性对照组,说明样品咖啡饮品可以显著增强小鼠NK细胞活性。
2.2感冒频率测试
对实施例1-6的用于提高免疫力的药酒进行提高免疫力效果测试,选择年龄20-60岁的免疫力低下、每年患感冒次数10次的患者180名,随机分成6组,每组30名,每位患者每周服用咖啡饮品一次。服用一年内感冒次数数据见表2。
表2患者病情数据表
结果表明通过每周长期服用增强免疫力的受试样品1-6组咖啡饮品,可以显著提高免疫力低下者的免疫力,减少患感冒的次数,受试样品1-3可以明显减少经常感冒患者每年感冒次数的作用,因此长期服用咖啡饮品可以用于提高机体免疫力。
2.3带状疱疹治疗
2.3.1治疗方法内服,患者服用相同种类和剂量的治疗带状疱疹的药物,即服用腺苷钴胺片和维生素B族,每天服药后1.5小时-3小时之间服用一杯本发明的咖啡保健品,7天为一个疗程,服用1个疗程;疗程中无需服用阿昔洛韦片。
2.3.2诊疗标准
疗效标准参照《中医病症判断疗效标准》中有关疗效标准。
治愈:临床症状全部消失,实验室检查正常;
显效:临床症状基本消失,试验室检查各相关指标接近正常水平。
有效:临床症状减轻,试验室检查各相关指标有所改善,体征有改善。
无效:临床症状无明显好转或加重。
针对本申请疗效标准为:
治愈:带状疱疹、皮损消失;
显效:带状疱疹基本消失,仍有轻微疼痛,皮肤散在结痂;
有效:有少量疱疹,局部疼痛;
无效:带状疱疹、皮损无改善。
从2019年至今通过本申请的咖啡治疗带状疱疹的患者共100例,男58例,女32例,年龄介于25-55岁,分为5组,每组20人,临床实验结果见表3。
表3带状疱疹临床实验结果
项目 | 人数 | 治愈 | 治愈率% | 显效 | 有效 | 无效 | 总有效率% |
实施例1 | 20 | 8 | 40 | 5 | 3 | 2 | 90 |
实施例2 | 20 | 10 | 50 | 7 | 2 | 1 | 95 |
实施例3 | 20 | 13 | 65 | 5 | 1 | 1 | 95 |
实施例4 | 20 | 15 | 75 | 5 | 0 | 0 | 100 |
对照组2 | 20 | 5 | 25 | 5 | 5 | 5 | 75 |
实验结果表明,实施例1-4制备的咖啡对带状疱疹具有较好的治疗效果,治愈率均在40%以上,有效率在90%以上,尤其是实施例4,通过合理控制中药组合物的含量,使得咖啡具有最优的治疗效果,治愈率为75%,总有效率为100%;对照组2中不添加灵芝多糖和灵芝总三萜(灵芝提取液),在一定程度上影响药物的治疗效果,尤其是治愈率明显降低,有效率也明显低于实施例1-4。
此外,本实验中未治愈的患者继续服用药物及咖啡液直至治愈,实施例1-4的服用平均时间分别为7天、6.2天、5天、3天,而对照组2的服用平均时间为13天。
由此可见,本发明的中药组合物通过采用特定的原料药组合及用量,对带状疱疹的治疗具有较好的效果,明显缩短治疗时间,本发明的咖啡具有明显治疗带状疱疹的作用。
第三部分:咖啡风味和产品稳定性
将实施例1-6和对照组1、2进行冲泡品尝,并将剩余咖啡液保留,盖盖,处于20-25℃保存,观察情况,以测试稳定性。具体情况见表4。
表4咖啡液风味与稳定性对比表
项目 | 风味 | 稳定性 |
实施例1 | 良好,没有明显的药味 | 储存4d后出现丝状毛 |
实施例2 | 良好,没有明显的药味 | 储存6d后出现丝状毛 |
实施例3 | 良好,没有明显的药味 | 储存6d后出现丝状毛 |
实施例4 | 良好,有麦芽香味 | 储存8d后出现丝状毛 |
实施例5 | 良好,有麦芽香味 | 储存8d后出现丝状毛 |
实施例6 | 良好,有麦芽香味 | 储存9d后出现丝状毛 |
对照组1 | 良好,没有明显的药味 | 储存8d后出现丝状毛 |
对照组2 | 良好,有麦芽香味 | 储存5d后出现丝状毛 |
由此可见,因木犀草苷(菊花提取液)含量大,则咖啡液的稳定性高,因此,添加了木犀草苷(菊花提取液)的咖啡液具有抗菌作用。实施例4和对照组2相比添加了灵芝总三萜的咖啡液更稳定。
第四部分:灵芝多糖和灵芝总三萜(灵芝提取液)制备方法
从实施例4-6和对照组1可以看出,添加了麦芽提取物的实施例4-6中灵芝制备的细胞内多糖和细胞外多糖得率为30mg/g相比对照组1得率为12mg/g,可见,麦芽提取物可以极大的提高多糖的含量,为灵芝多糖的制备提供有效碳源。添加了麦芽提取物的中间产物更有利于灵芝多糖和灵芝总三萜(灵芝提取液)的制备。
综上所述,仅为本发明的较佳实施例而已,并非用来限定本发明实施的范围,凡依本发明权利要求范围所述的形状、构造、特征及精神所为的均等变化与修饰,均应包括于本发明的权利要求范围内。
Claims (10)
1.一种用于提高免疫力的咖啡保健品,其特征在于,包括以下重量份数计的组分:
灵芝提取液0.8-3份,人参茎叶提取液0.6-3.2份,黄芪2-8份,黄精2-8份,炙甘草2-8份,百合2-6份,广藿香2-6份,薏苡仁2-6份,白芷2-6份,桑叶2-6份,菊花提取液2-5.8份,金银花2-6份,蒲公英2-6份,芦根2-6份,冻干咖啡粉0.8-3份、麦芽提取物1.6-6份,麦芽提取物中活性多糖含量为80%-92%。
2.如权利要求1所述的一种用于提高免疫力的咖啡保健品,其特征在于,冻干咖啡粉的咖啡因含量为0.8%;灵芝提取液为灵芝多糖和灵芝总三萜;人参茎叶提取液为人参茎叶总皂苷;菊花提取液为木犀草苷。
3.一种如权利要求1-2中任意一项所述的提高免疫力的咖啡保健品的制备方法,其特征在于,包括下列步骤:
a、制备初级混悬液:将黄芪,黄精,炙甘草,百合,广藿香,薏苡仁,白芷,桑叶,金银花,蒲公英和芦根2-6份制备成中药纳米粉A,过200-625目筛,称取一定量的前述中药纳米粉A加入到去离子水中,利用800rpm磁力搅拌10min混合均匀,制得中药粉混悬液,混悬液浓度比例为0.1-30%;混悬液首先转移至初级乳化分散机中进行初步粉碎一段时间,获得初级混悬液;中药粉混悬液在初级乳化分散机中的作用时间为5-30min,循环次数1-3次;
b、制备灵芝多糖和灵芝总三萜:
b1:将麦芽提取物分为两份:即B1和B2,其中B1是B2的0.5倍;
b2:将灵芝菌丝体溶解在去离子水中发酵24h-36h后,在灵芝菌丝体发酵液中加入鼠李糖乳杆菌LGG发酵液和麦芽提取物B1,并加入琥珀酸亚铁和葡萄糖酸辛,前述混合液发酵培养,发酵培养0.5-3天后,得到发酵液;
b3:将b2步骤中取得的发酵液中加入稀碱,在680w的超声功率下超声震荡15-25min,其中水相与固相比为28:1的条件下,得到细胞内多糖和细胞外多糖混合液;
c、将人参茎叶提取液和菊花提取液加入到b3中得到的细胞内多糖和细胞外多糖混合液,搅拌均匀,再加入麦芽提取物B2,得到混合液C:
d:制备中药纳米粉复合咖啡饮品:将混合液C转移至低温连续乳化机中,连续循环乳化粉碎,收集混悬液,在冷冻干燥程序下固化干燥,获得中药纳米粉D,加入冻干咖啡粉,并与中药纳米粉D混合均匀,得到提高免疫力的咖啡保健品。
4.一种如权利要求3所述的提高免疫力的咖啡保健品的制备方法,其特征在于,步骤a中的中药纳米粉与去离子水的比例为(1-1.5):(2-3)。
5.一种如权利要求4所述的提高免疫力的咖啡保健品的制备方法,其特征在于,步骤b2中灵芝菌丝体发酵液与鼠李糖乳杆菌LGG发酵液和麦芽提取物A1的比例为1:1。
6.一种如权利要求5所述的提高免疫力的咖啡保健品的制备方法,其特征在于,步骤b2中琥珀酸亚铁和葡萄糖酸辛与灵芝菌丝体发酵液的比例为0.5:1。
7.一种如权利要求6所述的提高免疫力的咖啡保健品的制备方法,其特征在于,步骤b3中细胞内多糖和细胞外多糖得率为20-30mg/g。
8.一种如权利要求7所述的提高免疫力的咖啡保健品的制备方法,其特征在于,步骤d中低温连续湿法分散乳化机采用0.03-0.8mm锆珠,锆珠添加量为腔体体积的65%-75%,转速为500rpm-2000rpm,时间为0.5h-6h;
纳米粉悬浮液在-50℃的温度下预冻时间为1h-2h;
纳米粉悬浮液冷冻干燥升华时间为12-48h,真空度为10-30Pa;
干燥粉末含水量小于5%,采用紫外线照射6-12h消毒。
9.一种如权利要求8所述的提高免疫力的咖啡保健品的应用方法,其特征在于,咖啡保健品中咖啡的浓度为2%-18%。
10.一种如权利要求9所述的提高免疫力的咖啡保健品的应用方法,其特征在于,提高免疫力的咖啡保健品可用于辅助治疗带状疱疹。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311036821.6A CN117356644A (zh) | 2023-08-17 | 2023-08-17 | 一种用于提高免疫力的咖啡保健品、制备方法及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311036821.6A CN117356644A (zh) | 2023-08-17 | 2023-08-17 | 一种用于提高免疫力的咖啡保健品、制备方法及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117356644A true CN117356644A (zh) | 2024-01-09 |
Family
ID=89401083
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311036821.6A Pending CN117356644A (zh) | 2023-08-17 | 2023-08-17 | 一种用于提高免疫力的咖啡保健品、制备方法及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117356644A (zh) |
-
2023
- 2023-08-17 CN CN202311036821.6A patent/CN117356644A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102188613B (zh) | 一种治疗糖尿病的中药制剂 | |
WO2015172618A1 (zh) | 一种抗肿瘤的中药及其制备方法和应用 | |
CN104815192A (zh) | 一种治疗高血压的药物组合物及其应用 | |
CN104306659A (zh) | 一种治疗2型糖尿病的中药组合物 | |
CN102847061A (zh) | 一种治疗小儿病毒性心肌炎的中药制剂及其制备方法 | |
CN105902827A (zh) | 提高人体免疫力的中药组合物及其制备方法 | |
CN104984292A (zh) | 一种治疗肺炎支原体肺炎的药物组合物及其制备方法 | |
CN103920011A (zh) | 用于产后肝郁气滞型缺乳的药物组合物及其制备方法 | |
CN117356644A (zh) | 一种用于提高免疫力的咖啡保健品、制备方法及其应用 | |
CN113750200A (zh) | 一种抗疲劳的方便食品人参黄精固体颗粒 | |
CN105998840A (zh) | 一种用于治疗虫咬皮炎的外用药膏及制备方法 | |
CN105561098A (zh) | 一种治疗糜烂性脚气的药物 | |
CN105343660A (zh) | 一种治疗周围性眩晕的中药制剂及其制造方法 | |
CN103860942A (zh) | 用于治疗痰浊结聚型鼻咽癌的药物及其制备方法 | |
CN104491318A (zh) | 一种治疗哮喘的中药制剂及其制备方法 | |
CN109464643A (zh) | 一种治疗慢性咳嗽的中药组合物及其制备方法 | |
CN103202964A (zh) | 益脑安神药酒 | |
CN117503833B (zh) | 一种食药两用的壮阳补肾中药组合物及其制备方法 | |
CN103110743B (zh) | 一种治疗或预防神经衰弱的中药组合物及其制备方法 | |
CN112402565B (zh) | 一种治疗膝关节滑膜炎的中药组合物及其制备方法 | |
CN102631486B (zh) | 一种保健组合物 | |
CN112402566B (zh) | 一种中药组合物在制备治疗膝关节滑膜炎的药物中的用途 | |
CN105012391B (zh) | 一种治疗病毒性感冒的药物及其制作方法 | |
CN104940653A (zh) | 一种用于治疗牛日射病和热射病的药物组合物及其制备方法 | |
CN102631493B (zh) | 一种保健组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |